Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Roche's Actemra falls short in Italian study in early-stage COVID-19 pneumonia
How Regeneron’s COVID-19 antibody cocktail cuts the risk of resistance
Providers to Congress: Patients will lose access to care without permanent expansion of telehealth
How to launch a drug in a pandemic? Here's how 4 drugmakers are using digital tools and fast footwork to do just that
FDA joins new, public-private COVID-19 diagnostic research accelerator effort
Mostashari: The survival of primary care is critical to fight COVID-19
Biopharma roundup: E.U. members line up for J&J vaccine; Actemra stumbles in COVID-19 pneumonia trial
Healthcare roundup: Blue Cross NC keeping expanded telehealth policies through 2020
Kaiser Permanente, Cambia CEOs: How payer execs adapted their leadership styles under COVID-19

Featured Story

Roche's Actemra falls short in Italian study in early-stage COVID-19 pneumonia

Thursday, June 18, 2020

In another challenge to the theory that IL-6 inhibitors can treat coronavirus patients, and Italian study found Roche’s anti-inflammatory drug Actemra didn’t help patients with early-stage COVID-19 pneumonia. But Roche is pressing ahead with its own tests in more severe patients—and ramping up manufacturing, too.

How Regeneron’s COVID-19 antibody cocktail cuts the risk of resistance

Thursday, June 18, 2020

Regeneron launched human trials of its anti-COVID cocktail REGN-COV2 last week, and now its scientists are explaining how they chose the two antibodies that comprise the treatment. The key was to thwart the ability of the virus to mutate by selecting antibodies that bind differently to their target, they explained in a new study.

Providers to Congress: Patients will lose access to care without permanent expansion of telehealth

Thursday, June 18, 2020

Patients will lose access to care if Congress doesn't take immediate steps to expand telehealth permanently, health executives told lawmakers Wednesday.

How to launch a drug in a pandemic? Here's how 4 drugmakers are using digital tools and fast footwork to do just that

Thursday, June 18, 2020

Launching a new drug is an arduous task even in the best of times, with months of effort and huge sums of money on the line. Add a global pandemic to that, and companies are faced with one of two options: Adapt or fail.

FDA joins new, public-private COVID-19 diagnostic research accelerator effort

Thursday, June 18, 2020

The FDA has joined a public-private diagnostic research project with the goal of bringing more real-world data to bear against the novel coronavirus, and gauging the accuracy of different kinds of tests.

Mostashari: The survival of primary care is critical to fight COVID-19

Thursday, June 18, 2020

The federal government has done "nothing special" to help primary care practices, according to Farzad Mostashari, M.D. Find out why Mostashari says primary care practices will the lifeblood of communities in the ongoing pandemic and in the "new normal."

Biopharma roundup: E.U. members line up for J&J vaccine; Actemra stumbles in COVID-19 pneumonia trial

Thursday, June 18, 2020

As European nations look to score advanced purchase deals for COVID-19 vaccines, some experts worry that low-income countries won't receive the treatments they need. Emergent invested $75 million to upgrade its gene therapy business, and Regeneron touted the strength of its antibody cocktail. Plus, Actemra sputtered in an early-stage COVID-19 pneumonia trial.

Healthcare roundup: Blue Cross NC keeping expanded telehealth policies through 2020

Thursday, June 18, 2020

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Kaiser Permanente, Cambia CEOs: How payer execs adapted their leadership styles under COVID-19

Thursday, June 18, 2020

The coronavirus pandemic forced the CEOs of some of the country’s biggest payers to rethink their approaches to leadership.

COVID-19 Tracker

Featured Story

Roche's Actemra falls short in Italian study in early-stage COVID-19 pneumonia

Top Stories

How Regeneron’s COVID-19 antibody cocktail cuts the risk of resistance

Providers to Congress: Patients will lose access to care without permanent expansion of telehealth

How to launch a drug in a pandemic? Here's how 4 drugmakers are using digital tools and fast footwork to do just that

FDA joins new, public-private COVID-19 diagnostic research accelerator effort

Mostashari: The survival of primary care is critical to fight COVID-19

Biopharma roundup: E.U. members line up for J&J vaccine; Actemra stumbles in COVID-19 pneumonia trial

Healthcare roundup: Blue Cross NC keeping expanded telehealth policies through 2020

Kaiser Permanente, Cambia CEOs: How payer execs adapted their leadership styles under COVID-19